AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Summary

RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young patients with relapsed or refractory acute leukemia.

Timeline

Start

2011-09

Primary completion

2014-07

Completion

2014-07

Drugs

Indications